Nuvalent combines deep expertise in structure-based design with clinical insights from physician-scientists to precisely inhibit clinically proven kinase targets and solve for the dual challenges of kinase resistance and selectivity.
The Kinase Resistance ProblemCancer cells are constantly mutating. Treatment with currently available kinase inhibitors often results in the emergence of cancer cells harboring new mutations. These mutations can provide resistance to existing therapies.
The Kinase Selectivity ProblemThe drug binding sites of different kinases are often very similar in structure, making it challenging to design molecules that uniquely inhibit a single target.
In some cases, the similarities between kinases can enable one molecule to be repurposed to treat multiple different tumor types. However, this compromise means allowing inhibition of off-target kinases, which can lead to significant adverse events and insufficient target inhibition, decreasing the duration of clinical responses.